Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $11.36.

VOR has been the subject of a number of research reports. JMP Securities reissued a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Robert W. Baird cut their target price on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research note on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a report on Tuesday, December 10th.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Vor Biopharma during the 4th quarter worth approximately $33,000. Virtu Financial LLC purchased a new stake in Vor Biopharma in the fourth quarter worth $60,000. XTX Topco Ltd bought a new position in Vor Biopharma in the fourth quarter worth $80,000. Rosalind Advisors Inc. bought a new position in Vor Biopharma in the third quarter worth $54,000. Finally, Trustees of Columbia University in the City of New York purchased a new position in Vor Biopharma during the fourth quarter valued at $102,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

Shares of NYSE:VOR opened at $1.08 on Friday. The business’s 50-day moving average is $1.33 and its 200-day moving average is $1.01. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $2.43. The company has a market capitalization of $74.17 million, a price-to-earnings ratio of -0.65 and a beta of -0.45.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.